Posts Tagged ‘annual-meeting’

Older Entries

Celldex Therapeutics Presents New Clinical Data From Phase 2 Study Of CDX-011 In Metastatic Melanoma At 46th Annual ASCO Meeting

9, Jun 2010

Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the presentation of promising clinical data on CDX-011 in metastatic melanoma at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The Phase 2 study has met its primary endpoint and the results support additional studies in this indication

Angiochem Presents Complete Phase 1 /2 Clinical Data For ANG1005: Further Demonstrating Benefits Of Targeting LRP-1 Pathway In Cancer

9, Jun 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL… (Source: Health News from Medical News Today)

Determining How Certain Recurrent Breast Cancer Patients Will Respond To Therapy

9, Jun 2010

Research introduced at SNM’s 57th Annual Meeting is expanding molecular imaging’s role in determining the best course of treatment for recurring breast cancer patients, while offering a means of evaluating certain therapies for potentially positive impact on their chance of survival.

Molecular Imaging Is Leading To More Individualized And Effective Treatment For Non-Hodgkin’s Lymphoma By Providing A Map To Guide The Path Of Therapy

9, Jun 2010

According to a study presented at SNM’s 57th Annual Meeting, molecular imaging can evaluate and optimize non-Hodgkin’s lymphoma therapy with Zevalin, a front-line radioimmunotherapy drug that uses a dose of radioactive material and mimics the body’s own immune response to target and kill cancer cells while sparing nearby healthy tissues… (Source: Health News from Medical News Today)

In High-Grade Gliomas Acute Toxicity Predicts Overall Survival

9, Jun 2010

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers from the Kimmel Cancer Center at Jefferson.


Older Entries

Copryright 2012 - Epione Medical Corporation | About us | Treatments | Contact us | Online Store

Share to Facebook Share to Twitter Stumble It Email This More...